These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 38615277)

  • 1. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
    Singer BA; Feng J; Chiong-Rivero H
    J Neurol; 2024 Jun; 271(6):3116-3130. PubMed ID: 38615277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    Filippi M; Amato MP; Centonze D; Gallo P; Gasperini C; Inglese M; Patti F; Pozzilli C; Preziosa P; Trojano M
    J Neurol; 2022 Oct; 269(10):5382-5394. PubMed ID: 35608658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and management of subclinical disease activity in early multiple sclerosis: a review.
    Ontaneda D; Chitnis T; Rammohan K; Obeidat AZ
    J Neurol; 2024 Apr; 271(4):1497-1514. PubMed ID: 37864717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    Filippi M; Danesi R; Derfuss T; Duddy M; Gallo P; Gold R; Havrdová EK; Kornek B; Saccà F; Tintoré M; Weber J; Trojano M
    J Neurol; 2022 Mar; 269(3):1670-1677. PubMed ID: 34626224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina.
    Alonso R; Casas M; Lazaro L; Liguori NF; Pita C; Cohen L; Rojas JI; Pappolla A; Patrucco L; Cristiano E; Burgos M; Vrech C; Piedrabuena R; Pablo L; Deri N; Luetic G; Miguez J; Cabrera M; Martinez A; Zanga G; Tkachuk V; Tizio S; Carnero Contentti E; Knorre E; Leguizamon F; Mainella C; Nofal P; Liwacki S; Hryb J; Menichini M; Pestchanker C; Garcea O; Silva B
    Mult Scler Relat Disord; 2023 Nov; 79():104935. PubMed ID: 37634468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
    Sharmin S; Roos I; Malpas CB; Iaffaldano P; Simone M; Filippi M; Kubala Havrdova E; Ozakbas S; Brescia Morra V; Alroughani R; Zaffaroni M; Patti F; Eichau S; Salemi G; Di Sapio A; Inglese M; Portaccio E; Trojano M; Amato MP; Kalincik T; ;
    Lancet Child Adolesc Health; 2024 May; 8(5):348-357. PubMed ID: 38547883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managed approaches to multiple sclerosis in special populations.
    Sperandeo K; Nogrady L; Moreo K; Prostko CR
    J Manag Care Pharm; 2011; 17(9 Suppl C):S1-19; quiz S20-1. PubMed ID: 22107156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
    Newsome SD; Binns C; Kaunzner UW; Morgan S; Halper J
    Neurol Ther; 2023 Dec; 12(6):1909-1935. PubMed ID: 37819598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving quality, affordability, and equity of multiple sclerosis care.
    Langer-Gould A; Klocke S; Beaber B; Brara SM; Debacker J; Ayeni O; Nielsen AS
    Ann Clin Transl Neurol; 2021 Apr; 8(4):980-991. PubMed ID: 33751857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
    Benallegue N; Rollot F; Wiertlewski S; Casey R; Debouverie M; Kerbrat A; De Seze J; Ciron J; Ruet A; Labauge P; Maillart E; Zephir H; Papeix C; Defer G; Lebrun-Frenay C; Moreau T; Berger E; Stankoff B; Clavelou P; Heinzlef O; Pelletier J; Thouvenot E; Al Khedr A; Bourre B; Casez O; Cabre P; Wahab A; Magy L; Vukusic S; Laplaud DA;
    JAMA Neurol; 2024 Mar; 81(3):273-282. PubMed ID: 38345791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis.
    Bandari DS; Sternaman D; Chan T; Prostko CR; Sapir T
    J Manag Care Pharm; 2012; 18(9):1-17. PubMed ID: 23206263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Socioeconomic, health-care access and clinical determinants of disease severity in Multiple Sclerosis in Chile.
    Ciampi E; Soler B; Uribe-San-Martin R; Jürgensen L; Guzman I; Keller K; Reyes A; Bravo-Grau S; Cruz JP; Cárcamo C
    Mult Scler Relat Disord; 2023 Oct; 78():104918. PubMed ID: 37562199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
    JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    Gelibter S; Saraceno L; Pirro F; Susani EL; Protti A
    J Neuroimmunol; 2024 Jun; 391():578368. PubMed ID: 38761652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
    Kopp TI; Blinkenberg M; Chalmer TA; Petersen T; Ravnborg MH; Soelberg Sørensen P; Magyari M
    Mult Scler; 2020 Jul; 26(8):964-975. PubMed ID: 31081451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
    Edan G; Le Page E
    Drugs; 2023 Oct; 83(15):1351-1363. PubMed ID: 37725259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
    Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
    J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
    Jouvenot G; Courbon G; Lefort M; Rollot F; Casey R; Le Page E; Michel L; Edan G; de Seze J; Kremer L; Bigaut K; Vukusic S; Mathey G; Ciron J; Ruet A; Maillart E; Labauge P; Zephir H; Papeix C; Defer G; Lebrun-Frenay C; Moreau T; Laplaud DA; Berger E; Stankoff B; Clavelou P; Thouvenot E; Heinzlef O; Pelletier J; Al-Khedr A; Casez O; Bourre B; Cabre P; Wahab A; Magy L; Camdessanché JP; Doghri I; Moulin S; Ben-Nasr H; Labeyrie C; Hankiewicz K; Neau JP; Pottier C; Nifle C; Collongues N; Kerbrat A;
    JAMA Neurol; 2024 May; 81(5):490-498. PubMed ID: 38526462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.